Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration

Phase 2

Terminated

• Conditions: Nonexudative Age Related Macular Degeneration
• Interventions: Drug: MC-1101; Drug: MC-1101 Vehicle

• Registration Number: NCT01601483
• Lead Sponsor: MacuCLEAR, Inc.

Brief Summary

This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2 years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for these patients.

An analysis of the primary and secondary endpoints will be conducted when all subjects have completed 12, 18 and 24 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-05-15
• Study First Submitted QC: 2012-05-17
• Study First Posted: 2012-05-18
• Study Start: 2012-10
• Primary Completion: 2013-03
• Study Completion: 2013-03
• Status Verified: 2014-04
• Last Update Submitted: 2014-04-24
• Last Update Posted: 2014-04-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Males and females age ≥ 50 years and ≤ 85 years;
• Females must be at least 1 year postmenopausal (after last menstrual period) or sterilized;
• Better than 20/80 ETDRS best corrected visual acuity;
• Mild to moderate nonexudative AMD (AMD steps 3 through 8 on Age-Related Eye Disease Study (AREDS) Report No. 17 grading scale);
• Willing to sign informed consent, comply with study protocol requirements, and undergo up to 2.5 hours of testing at each visit;

Exclusion Criteria

• Past or current exudative AMD or any geographic atrophy (on fundus autofluorescence) in study eye;
• Past or current other retinal or choroidal vasculopathy in study eye (e.g. pigment epithelial detachment, polypoidal choroidal vasculopathy, central serous retinopathy, retinal vein occlusion, sickle cell retinopathy);
• Uncontrolled hypertension (≥ 150 systolic or ≥95 diastolic);
• Diabetes mellitus;
• Glaucoma;
• Lens opacity ≥ grade 3 ARLNS on standard photographs;
• Unable to complete biophysical testing;
• Unable to give informed consent;
• Dilated pupil diameter less than 6 millimeters;
• Subjects with a history of a hypersensitivity reaction to the study drug or to any agent used in the components of the study assessment;
• Use of topical ocular medications (other than artificial tear products);
• Anticipated extra- or intraocular intervention during the study period;
• High myopia (refractive error spherical equivalent ≥ -6 diopters);
• Optic neuropathy;
• Neurological conditions that can impair vision (e.g. Parkinson's disease, multiple sclerosis, Alzheimer's disease);
• Liver disease (e.g. cirrhosis, hepatitis);
• History of GI surgery (e.g. bariatric surgery);
• Unwilling or unable to take an AREDS formula vitamin (without beta-carotene/vitamin A);
• Current or past use of chloroquine, hydroxychloroquine, chlorpromazine, thioridazine, quinine sulfate, clofazimine, cisplatin, carmustine (BCNU), or deferoxamine;
• Tobacco smoking (currently or within past 5 years);
• Contact lens wearers (not prepared to discontinue lens use);
• Ophthalmic surgery of any kind within 3 months prior to screening visit;
• Participation in any interventional clinical study requiring IRB approval within 3 months of enrollment;
• Currently being treated for cancer or any disease likely to adversely affect participation in a 2 year study;
• Known to have AIDS/HIV

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MC-1101 1% Ophthalmic Solution	MC-1101	-
Vehicle control	MC-1101 Vehicle	-

Primary Outcome Measures

Name	Time	Method
Visual Function	12 months	Primary efficacy assessment will be a comparison between groups of the change in visual function at 12 months with additional analyses at 18 and 24 months.

Secondary Outcome Measures

Name	Time	Method
Safety and Tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)	24 months	Evaluate the safety and tolerability (incidence and severity of adverse events, ocular irritability,and ocular hyperemia) of MC-1101 compared to vehicle control at each study visit following treatment for 2 years

Trial Locations

Locations (1)

University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States